Overall Score

Scale Market Position

TSHA remains a small-cap biotech with a market cap of about $2.06B and no evidence in the fresh data of durable scale advantages.

Revenue per share is still negligible at 0.0149, indicating the business has not yet built meaningful commercial scale.

Profitability Returns

Fresh metrics show deeply negative margins, including operating margin of -27.9% and net margin of -27.3%, which is inconsistent with moat-like economics.

Returns remain very weak, with ROIC at -34.5% and ROE at -56.2%, showing no sign of durable excess returns.

Balance Sheet Resilience

Liquidity is strong with a current ratio of 17.8 and cash ratio of 17.5, giving the company near-term flexibility.

Leverage appears manageable on a debt-to-equity basis at 0.14, but solvency remains poor and the business is still loss-making.

Pricing Power Unit Economics

Gross margin is high at 84.0%, but it is not translating into operating leverage because R&D and SG&A remain heavy relative to revenue.

Extremely high price-to-sales of 375x and negative free cash flow yield indicate the market is pricing in substantial future success rather than current moat strength.

Intangible Assets Switching Costs

The fresh data does not show evidence of patents, brand power, or customer lock-in that would support a durable moat.

High R&D intensity at 22.3% of revenue suggests ongoing pipeline investment, but not yet a proven competitive advantage.